-- For families living with familial adenomatous polyposis (FAP), the future can feel uncertain. FAP is a rare inherited condition that causes hundreds or even thousands of polyps to form in the colon and rectum. Without treatment, these polyps almost always turn into colorectal cancer.
Until now, the only proven way to manage FAP has been major surgery, often removing part or all of the colon. While lifesaving, these operations can have lifelong effects on health and quality of life.
Today, there is new hope. A Phase 3 clinical trial, called the Serenta Trial, is now enrolling patients to test a potential non-surgical treatment for FAP.
Learn more or check qualification criteria at serentatrial.com.
Introducing the Serenta Trial
The Serenta Trial is a FAP clinical trial testing a drug called eRapa. Unlike surgery, eRapa is taken as a capsule. It is designed to help slow or stop the growth of polyps in people with FAP.
Earlier studies showed promising results, and now researchers are moving into a Phase 3 clinical trial—the final stage before possible approval. This is the only ongoing Phase 3 clinical trial in familial adenomatous polyposis anywhere in the world.
Why This Trial Matters
- Non-surgical approach: Could offer an alternative to major surgery for FAP.
- FDA Fast Track status: Recognized as an important and urgent unmet need.
- Orphan Drug Designation: Special protections and focus on rare diseases.
- Global participation: Patients in the U.S. and Europe are being enrolled across multiple trial sites.
Dr. Marcia Cruz-Correa, one of the trial investigators, explains:
“Its Phase 2 data are promising and, if replicated in the Phase 3 Serenta trial, eRapa could become the first therapeutic treatment for FAP patients who currently have no options other than life-altering surgery”.
Joining the Trial
The Serenta Trial is seeking patients with confirmed familial adenomatous polyposis (FAP). For those who been diagnosed or know someone who has been diagnosed, they may be eligible to participate.
Participation may involve:
- Taking the study drug or a placebo capsule.
- Regular monitoring by a dedicated trial team.
- Access to expert medical care throughout the study.
Joining a clinical trial is a personal decision. For some, it’s a chance to access potential new treatments and contribute to research that could help future generations.
How to Learn More
For people living with familial adenomatous polyposis, now is the time to explore this opportunity.
Visit serentatrial.com to:
- Read full details of the Phase 3 clinical trial.
- See who may be eligible.
- Find participating sites.
A Step Toward a Brighter Future
For decades, families affected by FAP have faced a future dominated by surgery and cancer risk. The Serenta Trial represents a turning point—an opportunity to test a new approach that could change lives.
For anyone living with FAP, learn more about how to take part in this important study at serentatrial.com.
Contact Info:
Name: Steve Ellul
Email: Send Email
Organization: Serenta Trial
Website: https://serentatrial.com/
Release ID: 89172359
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.
